These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 12120097)

  • 1. Metabonomics: a platform for studying drug toxicity and gene function.
    Nicholson JK; Connelly J; Lindon JC; Holmes E
    Nat Rev Drug Discov; 2002 Feb; 1(2):153-61. PubMed ID: 12120097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach.
    Ebbels TM; Keun HC; Beckonert OP; Bollard ME; Lindon JC; Holmes E; Nicholson JK
    J Proteome Res; 2007 Nov; 6(11):4407-22. PubMed ID: 17915905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel genomic methods for drug discovery and mechanism-based toxicological assessment.
    Gant TW; Zhang SD; Taylor EL
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):72-80. PubMed ID: 19152215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing paradigm for prediction of development-limiting barriers and human drug toxicity.
    Sasseville VG; Lane JH; Kadambi VJ; Bouchard P; Lee FW; Balani SK; Miwa GT; Smith PF; Alden CL
    Chem Biol Interact; 2004 Nov; 150(1):9-25. PubMed ID: 15522258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. State-of-the-art genomics approaches in toxicology.
    Van Hummelen P; Sasaki J
    Mutat Res; 2010 Dec; 705(3):165-71. PubMed ID: 20466069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabonomics: a useful tool for the future surgeon.
    Goldsmith P; Fenton H; Morris-Stiff G; Ahmad N; Fisher J; Prasad KR
    J Surg Res; 2010 May; 160(1):122-32. PubMed ID: 19592031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational toxicology in drug development.
    Muster W; Breidenbach A; Fischer H; Kirchner S; Müller L; Pähler A
    Drug Discov Today; 2008 Apr; 13(7-8):303-10. PubMed ID: 18405842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit?
    Lühe A; Suter L; Ruepp S; Singer T; Weiser T; Albertini S
    Mutat Res; 2005 Aug; 575(1-2):102-15. PubMed ID: 15924886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive toxicogenomics in preclinical discovery.
    Barros SA; Martin RB
    Methods Mol Biol; 2008; 460():89-112. PubMed ID: 18449484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis.
    Lindon JC; Holmes E; Bollard ME; Stanley EG; Nicholson JK
    Biomarkers; 2004; 9(1):1-31. PubMed ID: 15204308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of metabonomics to identify impaired fatty acid metabolism as the mechanism of a drug-induced toxicity.
    Mortishire-Smith RJ; Skiles GL; Lawrence JW; Spence S; Nicholls AW; Johnson BA; Nicholson JK
    Chem Res Toxicol; 2004 Feb; 17(2):165-73. PubMed ID: 14967004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptomics in predictive toxicology.
    Storck T; von Brevern MC; Behrens CK; Scheel J; Bach A
    Curr Opin Drug Discov Devel; 2002 Jan; 5(1):90-7. PubMed ID: 11865677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo toxicity screening programs using metabonomics.
    Robosky LC; Robertson DG; Baker JD; Rane S; Reily MD
    Comb Chem High Throughput Screen; 2002 Dec; 5(8):651-62. PubMed ID: 12470262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicogenomics in biomarker discovery.
    Decristofaro MF; Daniels KK
    Methods Mol Biol; 2008; 460():185-94. PubMed ID: 18449488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology.
    Coen M; Holmes E; Lindon JC; Nicholson JK
    Chem Res Toxicol; 2008 Jan; 21(1):9-27. PubMed ID: 18171018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery.
    Fischer HP
    Biotechnol Annu Rev; 2005; 11():1-68. PubMed ID: 16216773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action.
    Ganter B; Tugendreich S; Pearson CI; Ayanoglu E; Baumhueter S; Bostian KA; Brady L; Browne LJ; Calvin JT; Day GJ; Breckenridge N; Dunlea S; Eynon BP; Furness LM; Ferng J; Fielden MR; Fujimoto SY; Gong L; Hu C; Idury R; Judo MS; Kolaja KL; Lee MD; McSorley C; Minor JM; Nair RV; Natsoulis G; Nguyen P; Nicholson SM; Pham H; Roter AH; Sun D; Tan S; Thode S; Tolley AM; Vladimirova A; Yang J; Zhou Z; Jarnagin K
    J Biotechnol; 2005 Sep; 119(3):219-44. PubMed ID: 16005536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.